Psoriasis Clinical Trial
A Study of DLX105-DMP in Subjects With Plaque Psoriasis
Summary
A Pilot, Open-Label Study in Subjects with Mild-to-Moderate Plaque Psoriasis to Investigate the Safety, Tolerability, and Preliminary Efficacy of a Four-Week Multidose Regimen of DLX105-DMP Administered to a Target Lesion
Eligibility Criteria
Key Inclusion Criteria:
Signed and dated informed consent.
Subjects aged 18-75 years.
Male subject, or if female, must be surgically sterile, post-menopausal, or using acceptable birth control.
Stable chronic mild-to-moderate plaque psoriasis.
Key Exclusion Criteria:
Non-plaque-type psoriasis only (e.g., pustular, erythrodermic and guttate psoriasis, palmar, or plantar) at Screening.
Drug-induced psoriasis (i.e., new onset or exacerbation from beta-blockers, calcium channel inhibitors or lithium) within 3 months prior to Day 1.
Ongoing use of psoriasis treatments or inadequate duration of washout prior to Day 1
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Alpharetta Georgia, 30022, United States
Philadelphia Pennsylvania, 19103, United States
San Antonio Texas, 78229, United States
Norfolk Virginia, 23502, United States
How clear is this clinincal trial information?